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perspective, and to compare the evidence across France,
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144 THE OCULAR SURFACE / APRIL 2016, VDED has a substantial economic burden, with indirect costs
making up the largest proportion of the overall cost due to a
substantial loss of work productivity. In addition, DED has a
substantial negative impact on physical, and potentially
psychological, function and HRQoL across the countries
examined. A number of studies also indicated that HRQoL
burden increases with the severity of disease. Additional
data are needed, particularly in Asia, in order to gain a
better understanding of the burden of DED and help inform
future health care resource utilization.
KEY WORDS Burden of disease, cost, dry eye disease,
quality of life, systematic literature reviewI. INTRODUCTIOND ry eye disease (DED) is a chronic and progressivemultifactorial disorder of the tears and ocular sur-face, which results in symptoms of discomfort and
visual disturbance, an unstable tear ﬁlm, and potential dam-
age to the ocular surface.1,2 Two major subtypes of DED
have been deﬁned: aqueous tear-deﬁcient DED and evapora-
tive DED. Aqueous tear-deﬁcient DED is subdivided into
Sjögren syndrome (SS) DED and non-SS DED.2 The most
common cause of evaporative DED is meibomian gland
dysfunction (MGD).2 The prevalence of DED appears to in-
crease with age, and has been reported to range from 5% to
33% of the adult population worldwide,3,4 making it an
important public health concern.
DED symptoms include irritation, stinging, dryness,
ocular fatigue, and ﬂuctuating visual disturbances.1,2 These
symptoms are likely to considerably impact a patient’s qual-
ity of life (QoL), particularly because many patients will
experience discomfort and visual problems over long pe-
riods of time. DED also is associated with an economic
burden on patients, the health care system, and society as
a result of direct medical costs relating to health care profes-
sional visits, pharmacologic therapies, and surgical proce-
dures, and indirect costs owing to loss of work days and
reduced productivity.OL. 14 NO. 2 / www.theocularsurface.com
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Abbreviations
CI Conﬁdence interval
DED Dry eye disease
DEDIQ Dry Eye Disease Impact Questionnaire
DEQ Dry Eye Questionnaire
EQ-5D EuroQol 5-Dimensions
ES Effect size
ESS Epworth Sleepiness Scale
ESSDAI European League Against Rheumatism
Sjögren’s Syndrome Disease Activity
Index
ESSPRI European League Against Rheumatism
Sjögren’s Syndrome Patient-Reported
Index
HADS Hospital Anxiety and Depression Scale
HAQ Health Assessment Questionnaire
HRQoL Health-related quality of life
IDEEL Impact of Dry Eye on Everyday Life
questionnaire
IDEEL-SB Impact of Dry Eye on Everyday Life
questionnaire-symptom bother
MCS Mental component summary
N/A Not available
NEI-VFQ National Eye Institute Visual Function
Questionnaire
NSAID Nonsteroidal anti-inﬂammatory drug
OR Odds ratio
OSDI Ocular Surface Disease Index
PCS Physical component summary
QoL Quality of life
RA Rheumatoid arthritis
SF-8 8-item Short-Form Health Survey
SF-36 36-item Short-Form Health Survey
SG Standard gamble
SLE Systemic lupus erythematosus
SLR Systematic literature review
SS Sjögren’s syndrome
TBUT Tear ﬁlm breakup time
TTO Time trade-off
VAS Visual analog scale
VFQ-25 25-item Visual Function Questionnaire
WHOQOL-
BREF
World Health Organization Quality of
Life-BREF scale
WLQ-J Japanese version of the Work Limitations
ECONOMIC AND HUMANISTIC BURDEN OF DRY EYE DISEASE / McDonald, et alGiven the high prevalence of DED worldwide, the over-
all humanistic and economic burden is likely to be consider-
able. However, no systematic review of the evidence across
geographic regions has been carried out to comprehensively
assess this burden. Such a review is needed to improve un-
derstanding of the extent of and gaps in the current litera-
ture on the burden of DED and to help identify future
research needs. We therefore conducted a systematic litera-
ture review to evaluate the burden of DED and its compo-
nents from an economic and health-related QoL (HRQoL)
perspective, and to compare the evidence across Europe
(France, Germany, Italy, Spain, and the United Kingdom),
North America (the United States) and Asia (Japan, China).Questionnaire
ZSAS Zung Self-Rating Anxiety Scale
ZSDS Zung Self-Rating Depression ScaleII. METHODS
A. Search Methods
PubMed/Medline, Embase, EconLit, Database of Ab-
stracts of Reviews of Effects, National Health Service Eco-
nomic Evaluation Database, Health Technology
Assessment database, and Evidence Review Group reports
were searched for literature on the economic or HRQoL
burden of DED published from January 1998 to July 2013.
The search was limited to published articles, supplemented
with Internet searches to identify additional data when
necessary (e.g., treatment guidelines not indexed in publica-
tion databases). Proceedings from conferences and clinical
trial registries were not considered. The search terms forTHE OCULAR SURFACE / APRIL 2016, VOLPubMed are shown in Table 1; other databases were
searched using comparable terms.B. Selection Criteria
Article selection criteria included English language arti-
cles and reports of original data relevant to the economic or
HRQoL burden of DED in at least one of eight prespeciﬁed
countries: China, France, Germany, Italy, Japan, Spain, the
United Kingdom, and the United States.. 14 NO. 2 / www.theocularsurface.com 145
Table 1. PubMed search terms*
Overall (“dry eye syndromes” [MeSH]) OR (“dry” [All Fields] AND “eye”
[All Fields] AND “syndromes” [All Fields]) OR (“dry eye
syndromes” [All Fields]) OR (((“dry” [All Fields] AND “eye” [All
Fields]) OR (“dry eye” [All Fields])) AND ((“disease” [MeSH]) OR
(“disease” [All Fields]))) AND
Economic burden (“economics” [MeSH] OR “cost” [All Fields] OR “econ”* [All
Fields] OR “burden” [All Fields] OR “healthcare resource use”
[All Fields] OR “healthcare resource utilization” [All Fields] OR
“indirect cost” [All Fields] OR “productivity” [All Fields]) OR
HRQoL (“qol” OR “quality of life” OR “patient satisfaction” [MeSH] OR
“utility” OR “patient reported outcomes” OR “time tradeoff”
OR “TTO” OR “activities of daily living” [All Fields] OR “ADL” OR
“social impact”)
* The “dry eye syndromes” MeSH includes “keratoconjuctivitis sicca,” “Sjögren’s syndrome,” and “xerophthalmia.” The “economics” MeSH in-
cludes “cost and cost analysis,” “health care costs” (direct service costs, drug costs, employer health costs, hospital costs), “cost of illness,” and
“health expenditures.”
ADL, activities of daily living; MeSH, Medical Subject Heading; TTO, time trade-off.
Search ﬁlters: humans, 15-year time frame (January 1998 to July 2013).
ECONOMIC AND HUMANISTIC BURDEN OF DRY EYE DISEASE / McDonald, et alC. Data Collection and Extraction
Preferred Reporting Items for Systematic Reviews and
Meta-Analyses guidelines were followed. One reviewer
screened all titles and abstracts retrieved from the database
searches, followed by full-text review of selected articles.
References of systematic reviews and other articles were
manually searched for additional appropriate citations. A
standardized table was used to extract and record relevant
data from selected publications, including author/year/jour-
nal, study objective, brief description of the study popula-
tion, study outcome, key summarized ﬁndings, and study
limitations.III. RESULTS
Of 76 titles/abstracts reviewed on the economic burden
of DED and 263 on the HRQoL burden, 12 and 20 articles,
respectively, met the selection criteria as stated in the
Methods section, and were included in the review
(Figure). Tables 2 and 3 provide a summary of the literature
identiﬁed. In a narrative synthesis of the results, ﬁndings on
the economic burden of DED are presented according to to-
tal direct medical costs, treatment utilization/costs, and pro-
ductivity loss and indirect costs, which are split further by
geographic region. Of the 12 articles describing economic
burden, only 45-8 gave the costs of over-the-counter prepa-
rations. Findings on the HRQoL burden of DED are pre-
sented by geographic region.
A. Economic Burden of DED
1. Total Direct Medical Costs
a. Europe
In the European countries of interest, our literature
search identiﬁed a single source of data on direct medical
costs. This was a cost analysis study in which the cost of
DED for 2003 to 2004 was investigated in France, Germany,
Italy, Spain, Sweden, and the United Kingdom. (Swedish146 THE OCULAR SURFACE / APRIL 2016, Vdata are not reported because Sweden was not among the
prespeciﬁed countries for this review.)9 Clegg et al per-
formed a systematic literature search followed by interviews
to evaluate the management practices of 23 randomly
selected consultant ophthalmologists. The total annual cost
of ophthalmologist-managed care for 1,000 patients with
DED was estimated to range from US $0.27 million in
France to US $1.10 million in the United Kingdom. This es-
timate includes the cost of specialist visits, diagnostic tests,
and pharmacologic and surgical interventions, with the pro-
portions of each differing across countries. The largest pro-
portion of costs was accounted for by prescription drugs in
Germany and the United Kingdom, diagnostic tests in Italy,
and specialist visits in France and Spain.b. United States
In the United States, a key source of data on the eco-
nomic burden of DED (extracted for 2008) is a study by
Yu et al among 2,171 patients with DED recruited from
the Sjögren’s Syndrome Foundation and Harris Interactive’s
Harris Poll.8 With the assumption that treatment would not
change signiﬁcantly over 1 year, a decision analytic model
was used to calculate the annual cost of managing a cohort
of patients with DED. Direct costs consisted of ocular lubri-
cant treatment, cyclosporine, punctal plugs, physician visits,
and nutritional supplements. The annual total direct cost for
DED to the US health care system was estimated to be US
$782,673 for a cohort of 1,000 patients.8 Factoring in the
estimated number of individuals aged 50 years or older
with DED in the United States (men, 1.68 million; women,
3.23 million10,11), the overall burden of DED on the health
care system was calculated at US $3.84 billion. Direct costs
also increased with disease severity; the average annual
direct medical cost per patient for those with mild, moder-
ate, and severe DED symptoms was estimated at US $678,
US $771, and US $1,267, respectively.8 In a second largeOL. 14 NO. 2 / www.theocularsurface.com
Articles identified through
database searches:
PubMed: 52
Embase: 40
Other databases: 0
Title/abstracts reviewed: 76
Duplicates removed: 16
Full text reviewed: 28
Excluded: 48
Comorbidity: 2
Focus not on economics: 35
Geography/limited cohort: 5
Indication not of interest: 6
Articles included: 12
Excluded: 16
Abstract only: 2
Geography: 1
Indication not of interest: 1
Limited cohorts/applicability: 7
No original data: 5
 Economic burden of DED
Articles identified through
database searches:
PubMed: 171
Embase: 138
Other databases: 0
Title/abstracts reviewed: 263
Duplicates removed: 46
Full text reviewed: 96
Excluded: 167
Indication not of interest/not DED specific: 43
Outcomes not of interest/not HRQoL specific: 124
Articles included: 20
Excluded: 76
Focus not on HRQoL: 12
Full text not available/abstract only: 7
Geography: 28
Indication not of interest: 8
Language other than English: 3
Letter to the editor: 2
No original data: 5
Results relate to treatment only/no control group: 10
Sample size of only 3: 1
 HRQoL burden of DED
A
B
Figure 1. Preferred Reporting Items for
Systematic Reviews and Meta-Analyses
ﬂow diagram. DED, dry eye disease;
HRQoL, health-related quality of life.
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Table 2. Literature identiﬁed on the economic burden of DED
Reference Country Methods Study population (n)
Year cost extracted (if
stated) Key cost data
Europe
Clegg et al 20069 France, Germany, Italy,
Spain, and the United
Kingdom
d SLR plus interviews of
ophthalmologists
DED (model cohort,
Nz1,000)
2003e2004 d Direct cost analysis
- Total annual cost of
ophthalmologist-
managed care for
1,000 patients with
DED: France, US
$273,000; Germany,
US $536,000; Italy,
US $645,000; Spain,
US $765,000; United
Kingdom, US
$1,100,000
- Annual prescription
drug costs per 1,000
patients with DED:
France, US $22,000;
Germany, US
$227,000; Italy, US
$51,000; Spain, US
$256,000; United
Kingdom, US
$535,000
United States
Brown et al 20095 United States d Cost-utility study of
topical cyclosporine for
treatment of DED
DED (N¼877, of whom
n¼270 had SS)
2007 d Direct cost analysis
- Total annual cost of
topical cyclosporine
per patient: US
$1,276
- Total annual cost of
preservative-free
artiﬁcial tears per
patient (Refresh
Lubricant Eye Drops,
Allergan, Inc., Irvine,
CA): US $96
Cross et al 200215 United States d Single-center retrospec-
tive chart review inves-
tigating clinical,
economic, and patient-
reported outcomes
DED (N¼181) 1995e2000 d Total medication orders,
including those used for
DED (NSAIDs, antihista-
mines, artiﬁcial tears,
ophthalmic antibiotics,
Table 2. continues on the following page
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Table 2. Literature identiﬁed on the economic burden of DED (continued from previous page )
Reference Country Methods Study population (n)
Year cost extracted (if
stated) Key cost data
related to topical cyclo-
sporine A
and ophthalmic/antibi-
otic steroid combina-
tions) decreased 55%
after patients with DED
were treated with
topical cyclosporine A
Dalzell 200314 United States d Review article contain-
ing original data from a
poster53
DED (N¼74) e d Direct cost analysis
- Cost of palliative
medications, punctal
plugs, and surgery
for DED: US
$357,050/500,000
lives
d Indirect cost analysis
- Patients with DED:
average of 184 work
days per year of
reduced productiv-
ity; estimated annual
cost of US $5,362 per
patient
Fiscella et al 200812 United States d Retrospective claims
analysis
Patients receiving topical
cyclosporine (n¼9,065)
and punctal plugs
(n¼8,758)
2004e2005 d Direct cost analysis
- Total annual health
plan costs: US $3.05
million for topical
cyclosporine cohort,
US $3.28 million for
punctal plug cohort
(US $2.24 million for
initial punctal plug
procedures plus US
$1.04 million for
further procedures
during follow-up)
- Mean annual pre-
scription cost paid
by health plan per
patient for topical
cyclosporine cohort:
US $336
- Mean annual cost
per patient for
Table 2. continues on the following page
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Table 2. Literature identiﬁed on the economic burden of DED (continued from previous page )
Reference Country Methods Study population (n)
Year cost extracted (if
stated) Key cost data
punctal plug proce-
dures in punctal
plug cohort: US $375
Galor et al 201213 United States d Survey Participants representative
of the US population; using
topical cyclosporine and/or
blephamide (N¼147)
2001e2006 d Direct cost analysis
- Mean medication
expenditure per pa-
tient, inﬂated to
2009 US $ amounts:
2001e2002, US $55
(n¼29); 2003e2004,
US $137 (n¼32);
2005e2006, US $299
(n¼86)
- Mean annual DED
medication expendi-
tures per patient (fe-
males vs males): US
$244 versus US $122;
P<.0001
Hirsch 200316 United States d Review article contain-
ing original data from a
congress abstract54
SS (N¼N/A) e d DED symptoms inter-
fered annually with lei-
sure activities on
123 days
d Patients absent from
work for 5 days owing to
DED symptoms/treat-
ment and worked
208 days with symptoms
Patel et al 201117 United States d Cross-sectional, web-
based survey
d Participants were
currently employed, had
patient-reported physi-
cian-diagnosed DED,
and OSDI score 13
DED (N¼617), of whom
had mild DED (n¼124),
moderate DED (n¼132),
severe DED (n¼361)
e d All three severity groups
reported reduced pro-
ductivity at work
d Signiﬁcantly greater re-
ductions in productivity
for moderate and severe
DED versus mild DED
(P<.05)
d Impairment in ability to
perform daily activities
signiﬁcantly greater for
patients with severe
Table 2. continues on the following page
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Table 2. Literature identiﬁed on the economic burden of DED (continued from previous page)
Reference Country Methods Study population (n)
Year co extracted (if
ated) Key cost data
versus mild/moderate
DED (P<.05)
Reddy et al 20047 United States d Review of Medline arti-
cles plus clinician
interviews
DED 2003 d Direct cost analysis (unit
cost per visit/treatment
[range]):
- Ophthalmologist: US
$68 (US $61e124)
- General practitioner:
US $48 (US $21e88)
- Optometrist: US $68
(US $61e124)
- Tear replacements:
US $5e17
- Lubricant eye oint-
ment: US $11e12
- Cyclosporine eye
drops (single dose
[32 vials]): US $115
Yu et al 20118 United States d Survey DED (N¼2,171) 2008 d Direct cost analysis (cat-
egories: ocular lubricant
treatment, cyclosporine,
punctal plugs, physician
visits, and nutritional
supplements)
- Annual cost for pa-
tients seeking medi-
cal care: US $783 per
patient (range, US
$757e809); overall
burden of DED for
US health care sys-
tem, US $3.84 billion
- Annual medical cost
per patient: mild
DED, US $678; mod-
erate DED, US $771;
severe DED, US
$1,267
d Indirect cost analysis
- Annual cost to US
society: US $11,302
Table 2. continues on the following page
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Table 2. Literature identiﬁed on the economic burden of DED (continued from previous page )
Reference Country Methods Study population (n)
Year cost extracted (if
stated) Key cost data
per patient and US
$55.4 billion overall
- In a cohort of
workers, total pro-
ductivity loss:
- US $12,569e18,168 per
year per patient
- Mean lost no. of work
days per year per pa-
tient: mild DED,
8.4 days; moderate DED,
3.7 days; severe DED,
14.2 days
- Mean lost no. of work
days per year per pa-
tient owing to affected
performance: mild DED,
91 days; moderate DED,
94.9 days; severe DED,
128.2 days
Asia
Mizuno et al 20126 Japan d Prospective cohort study DED (N¼118) 2008 d Direct cost analysis (cat-
egories: medical and
drug costs, including
costs related to artiﬁcial
tear use and punctal
plugs)
- Total annual cost per
patient: US $530
(U52,467)
- Annual drug costs
per patient ( SD):
US $323  $219
(U32,000  U21,675)
- Annual clinical costs
per patient ( SD):
US $165  $101
(U16,318  U9961)
- Annual costs of
punctal plugs: US
$42  $181
(U4,149  U17,876)
Table 2. continues on the following page
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Table 2. Literature identiﬁed on the economic burden of DED (continued from previous page )
Reference Country Methods Study population (n)
Year cost extracted (if
stated) Key cost data
Yamada et al 201218 Japan d Internet online survey
based on the WLQ-J
d Used the general con-
sumer panel run by
Cross Marketing Inc.
(Tokyo, Japan)
Deﬁnitive DED (n¼69),
marginal DED (n¼128),
self-reported DED (n¼80),
controls (n¼78)
2011 d Indirect cost analysis
- Annual cost of work
productivity loss
associated with DED
per patient: US $741
(U59,758)
d Cost of work productiv-
ity loss per patient:
deﬁnitive DED, US $799;
marginal DED, US $58;
self-reported DED, US
$1,036
d Degree of work perfor-
mance loss: 5.65% (deﬁ-
nite DED), 4.37%
(marginal DED), 6.06%
(self-reported DED),
4.27% (controls)
d Productivity signiﬁcantly
lower in patients with
self-reported DED versus
controls (P<.05)
- No signiﬁcant differ-
ences in subscale
scores of time man-
agement, physical
demands, and
output demands for
patients with DED
versus controls.
However, mental/
interpersonal score
signiﬁcantly lower in
the deﬁnite DED
(P<.05) and self-re-
ported DED (P<.01)
groups versus
controls
CI, conﬁdence interval; DED, dry eye disease; N/A, not available; NSAID, nonsteroidal anti-inﬂammatory drug; OSDI, Ocular Surface Disease Index; RA, rheumatoid arthritis; SLR, systematic literature
review; SS, Sjögren’s syndrome; WLQ-J, Japanese version of the Work Limitations Questionnaire.
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Table 3. Literature identiﬁed on DED-related HRQoL
Reference Country Methods HRQoL instruments used
Study population
(n) Key ﬁndings
Europe
Denoyer et al 201220 France d Prospective case-control study
assessing time course of higher order
aberrations/modulation transfer
function
d OSDI DED (n¼40),
controls (n¼40)
d Signiﬁcantly higher OSDI overall
score/subscores in patients with DED
versus controls (P<.01 for all
comparisons)
d Higher order aberration progression
index correlated with OSDI overall
score/ocular symptoms and OSDI
vision-related activities of daily living
subscores
d OSDI overall score negatively corre-
lated with TBUT/Schirmer’s test
Deschamps et al
201321
France d Prospective case-control study to
assess visual performance while
driving
d OSDI DED (n¼20),
controls (n¼20)
d Signiﬁcantly higher OSDI overall
score/subscores in patients with DED
versus controls (P<.01 for all
comparisons)
Jacobi et al 201123 Germany d Prospective nonrandomized single-
center study evaluating tear ﬁlm os-
molarity using electrical impedance
technology
d OSDI DED (n¼133),
controls (n¼95)
d Signiﬁcantly higher OSDI score in pa-
tients with DED versus controls
(P<.05)
Iannuccelli et al 20127 Italy d Cross-sectional survey to assess ﬁbro-
myalgia symptoms in SS and SLE
d Fatigue VAS
d Pain VAS
d HAQ
d ZSDS
d ZSAS
Primary SS (n¼50),
SLE (n¼50)
d No signiﬁcant differences in fatigue
and pain VAS scores, HAQ, ZSDS, and
ZSAS (SLE vs primary SS)
d Mean (SD) ZSDS scores:
48.24  17.20 versus 49.46  13.63
(SLE vs primary SS)
d Mean (SD) ZSAS scores:
50.04  13.48 versus 48.86  11.16
(SLE vs primary SS)
Belenguer et al
200524
Spain d Survey to evaluate HRQoL in primary
SS and correlation with clinical
features
d Patients seen consecutively in outpa-
tient clinic
d SF-36 Primary SS
(n¼110),
controls
(n¼9,151)
d All SF-36 scale scores signiﬁcantly
lower for patients with primary SS
versus controls (role-physical, role-
emotional, vitality, mental health, so-
cial functioning, bodily pain, physical
functioning, and general health;
P<.001 for all comparisons)
García-Catalán et al
200922
Spain d Cross-sectional, case-control study
evaluating correlations between
HRQoL and clinical signs
d OSDI
d VFQ-25
DED (n¼19),
controls (n¼21)
d OSDI total score signiﬁcantly higher
(P<.001) and VFQ-25 total score
signiﬁcantly lower (P¼.006) for pa-
tients with DED versus controls
Table 3. continues on the following page
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Table 3. Literature identiﬁed on DED-related HRQoL (continued from previous page )
Reference Country Methods HRQoL instruments used
Study population
(n) Key ﬁndings
d In patients with DED, signiﬁcant cor-
relations (P<.05) for:
- OSDI with VFQ-25 total score (r¼
0.62)
- TBUT with corneal staining (r¼
0.50) and Schirmer’s test
(r¼0.66)
- BUT with OSDI total score, OSDI
symptoms, and OSDI triggers (r¼
e0.56, e0.56, and e0.60,
respectively)
- Corneal staining with OSDI total
score and OSDI symptoms
(r¼0.55 and 0.54, respectively)
- BUT with VFQ-25 total score, VFQ-
25 ocular pain, mental function,
and role function (r¼0.56, 0.51,
0.63, and 0.56, respectively)
- Corneal staining with VFQ-25 total
score, VFQ-25 ocular pain, and
near vision (r¼0.57, 0.49, and
e0.62, respectively)
Bowman et al 200425 United
Kingdom
d Survey to assess fatigue/discomfort in
primary SS, SLE, and RA
d SF-36
d WHOQOL-BREF
d Symptoms of fatigue/
generalized discomfort
Primary SS
(n¼137), RA
(n¼74), SLE
(n¼66),
controls
(n¼103)
d SF-36 and WHOQOL-BREF scales
signiﬁcantly different (P<.008) for all
disease groups versus controls
d Somatic fatigue in the fatigue/gener-
alized discomfort questionnaire
signiﬁcantly more severe over the
previous 2 weeks for all disease
groups versus controls (P<.001)
d Patients with primary SS had signiﬁ-
cantly impaired mental fatigue versus
controls (P<.001)
Buchholz et al 200619 United
Kingdom
d Utility assessment study evaluating
impact of DED
d Survey via interactive utility assess-
ment software
d TTO and SG for utility
d VFQ-25
d OSDI
DED (N¼44), of
whom had
mild/moderate DED
(n¼24), severe
DED (n¼20)
d Utilities for DED were in the range of
conditions accepted as lowering
health utilities
- Utilities for severe DED were
similar to those reported for se-
vere angina, dialysis, or disabling
hip fracture
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Table 3. Literature identiﬁed on DED-related HRQoL (continued from previous page)
Reference Country Methods HRQoL instruments used
Study population
(n) Key ﬁndings
d Patient-assessed severity correlated
with VFQ-25 scores (P¼.0016) and
OSDI scores (P¼.0005)
d Statistically signiﬁcant differences in
mean VFQ-25 score (self-rated mild/
moderate DED [78.1] versus severe
DED [64.5]; P¼.005)
d Mean utilities for scenarios of DED
severity levels slightly higher for mild
to moderate versus severe DED (0.72
vs 0.61)
Hackett et al 201226 United
Kingdom
d Case-control study to assess function
in primary SS and relationship with
disease activity, symptoms, and
HRQoL
d HAQ
d Proﬁle of fatigue
d Pain, VAS
d HADS
d ESSPRI
d ESSDAI
d EQ-5D
d ESS
Primary SS
(n¼69), controls
(n¼69)
d Signiﬁcantly greater functional
impairment across all activity domains
(mean  SD improved HAQ total
scores, primary SS vs controls: 24  25
vs 9  19; P¼.0002)
d Primary SS: functional impairment
signiﬁcantly associated with physical
fatigue (P<.0001), pain (VAS;
P<.0001), depression (HADS;
P<.0001), total symptom burden
(ESSPRI; P<.0001), systemic disease
activity (ESSDAI; P¼.001), quality of life
(EQ-5D VAS and EQ-5D TTO; P<.0001
for each), daytime somnolence (ESS;
P¼.02), anxiety score (HADS; P¼.03)
Rostron et al 200228 United
Kingdom
d Cross-sectional study comparing
health status of patients with primary
SS and xerostomia
d SF-36 Primary SS
(n¼43), patients
with non-SS
reporting
xerostomia (n¼40)
d Lower mean SF-36 scores across all
eight scales (primary SS vs normative
community data)
Stevenson et al
200429
United
Kingdom
d Cross-sectional study assessing anxi-
ety/depression in primary SS
d HADS Primary SS
(n¼40),
controls (n¼40)
d Signiﬁcantly higher mean (SD) scores
for depression: primary SS, 6 (4.5);
controls, 3.7 (2.9); standardized mean
difference (95% CI): 0.600 (0.15e1.05)
d No signiﬁcant difference in mean
scores for anxiety (primary SS vs
controls)
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Table 3. Literature identiﬁed on DED-related HRQoL (continued from previous page )
Reference Country Methods HRQoL instruments used
Study population
(n) Key ﬁndings
North America
Abetz et al 201135 United
States
d Validation study of IDEEL
d Differences between severity evalu-
ated by recruited diagnosis (non-SS
DED, SS, control), clinician report
(mild, moderate, severe symptoms),
and patient report (no DED, very mild/
mild, very severe/severe)
d IDEEL
d SF-36
d EQ-5D
Non-SS DED
(n¼130), SS
(n¼32), controls
(n¼48)
d IDEEL: signiﬁcant (P<.0001) differ-
ences in all mean dimension scores
(except satisfaction with treatment
effectiveness) for different severity
levels across the three severity criteria
(recruited diagnosis, clinician report,
or patient report)
d SF-36: signiﬁcant (P<.0001) differ-
ences in PCS scores between different
severity levels across the three
severity criteria. Differences across
severity levels for MCS scores were
only signiﬁcant for clinician report and
patient report
d EQ-5D: signiﬁcant (P<.0001) differ-
ences in mean dimension scores for
the different severity levels across the
three severity criteria
Fairchild et al 200834 United
States
d Prospective randomized study to
assess utility of IDEEL-SB to discrimi-
nate self-assessed DED severity and
changes in condition after treatment
(lubricating eye drops)
d IDEEL-SB DED (N¼74) d At baseline, mean ( SD) IDEEL-SB
score: mild, 40.0 ( 7.5); moderate,
50.6 ( 11.0); severe, 64.3 ( 8.0)
d Mean IDEEL-SB score signiﬁcantly
correlated with self-reported severity
(P¼.001)
Mertzanis et al
200537
United
States
d Part of IDEEL validation study
d The relative burden of DED was
compared using SF-36 responses from
patients with DED and controls
against US norms (general population
from the SF-36 Health Survey manual
and interpretation guide55)
d SF-36 Non-SS DED
(n¼130), SS
(n¼32), controls
(n¼48)
d Patients with non-SS DED: lower SF-36
scores versus adjusted norm for role-
physical (ES, e0.07), bodily pain (ES,
0.08), vitality (ES, e0.11); higher
physical functioning (ES, 0.09), general
health (ES, 0.13), social functioning
(ES, 0.19), role-emotional (ES, 0.07),
and mental health (ES, 0.06) versus
adjusted norm
d Patients with SS: all SF-36 scale scores,
except mental health (ES, 0.12), lower
versus adjusted norm (ES range,
e0.16 to e0.99)
d Clinician-reported severity levels
versus norms:
- Patients with mild DED: lower
scores for role-physical, bodily
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Table 3. Literature identiﬁed on DED-related HRQoL (continued from previous page)
Reference Country Methods HRQoL instruments used
Study population
(n) Key ﬁndings
pain, vitality, and general health
(ES range, e0.01 to e0.17); higher
scores for physical functioning,
social functioning, role-emotional,
and mental health (ES range, 0.03
e0.13)
- Moderate DED: lower scores on
role-physical (ES, e0.32), bodily
pain (ES, e0.21), vitality (ES,
e0.42), role-emotional (ES, e0.22),
and mental health (ES, e0.19)
- Severe DED: lower scores versus
adjusted norm across all domains
(ES range, e0.38 to e0.91), with
the exception of role-emotional
(ES, e0.13) and mental health (ES,
e0.23)
d Patients with non-SS DED and SS:
when DED severity is assessed by
clinician, mental health is unaffected
by DED symptoms, but when self-
reported symptoms are severe, there
is a negative effect on mental health
(ES, e0.14)
Miljanovic et al
200739
United
States
d Cross-sectional study to evaluate
impact of DED on vision-related QoL
d Participants from Women’s Health and
Physicians’ Health studies
d 11-item questionnaire
assessing vision-related
QoL
DED (n¼190),
controls (n¼399)
d Patients with DED signiﬁcantly more
likely to report problems with reading
(OR, 3.64; 95% CI, 2.45e5.40; P<.001),
doing professional work (OR, 3.49;
95% CI, 1.72e7.09; P¼0.001), using a
computer (OR, 3.37; 95% CI, 2.11
e5.38; P<.001), watching television
(OR, 2.84; 95% CI, 1.05e7.74; P¼.04),
daytime driving (OR, 2.80; 95% CI, 1.58
e4.96; P<.001), or nighttime driving
(OR, 2.20; 95% CI, 1.48e3.28; P<.001)
Nichols et al 200233 United
States
d Validation study of VFQ-25
d Recruited from university-based
optometry practice
d VFQ-25 DED (N¼75) d Mean ( SD) ocular pain subscale
score signiﬁcantly different between
moderate to severe DED (60.8  14.1
points) and milder DED (71.8  19.2
points; visit 1: Wilcoxon rank-sum,
P¼.009)
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Table 3. Literature identiﬁed on DED-related HRQoL (continued from previous page)
Reference Country Methods HRQoL instruments used
Study population
(n) Key ﬁndings
Rajagopalan et al
200536
United
States and
Canada
d Validation study of SF-36, EQ-5D, and
IDEEL
d Severity was assessed based on diag-
nosis (non-SS DED, SS, control), pa-
tient report (none, very mild, mild,
moderate, severe, extremely severe)
and clinician report (none, mild,
moderate, severe)
d Assessment of patient-reported
severity provided by DEQ
d SF-36
d EQ-5D
d IDEEL
Non-SS DED
(n¼130), SS (n¼32),
controls (n¼48)
d Signiﬁcantly different (P<.05) SF-36
scores between various severity levels,
except for role-emotional by patients’
recruited diagnosis and self-rated
severity; physical functioning by
clinician-rated severity and self-rated
severity; and bodily pain by clinician-
rated severity
d Signiﬁcant differences in EQ-5D QoL
scores (P<.05) and VAS (P<.0001)
across all severity measures
d For recruited diagnosis and clinician-
rated severity, signiﬁcant differences
in IDEEL scores between different
levels of severity (P<.0001) in all
scores except treatment satisfaction
Schiffman et al
200338
United
States
d Survey to determine utilities for DED
d Patients with mild, moderate, or se-
vere DED
d TTO dry eye utilities
d SF-36
d VFQ-25
DED (N¼40) d Mean TTO utilities for moderate (0.78)
and severe DED (0.72) were similar to
historical reports for moderate (0.75)
and more severe (Class III/IV) angina
(0.71), respectively
d Signiﬁcant associations were seen
with the SF-36 physical functioning,
role-physical, bodily pain, and vitality
subscales, and the SF-36 PCS score (all
P.045); and with the VFQ-25 com-
posite score (P¼.037)
Sullivan et al 20040 United
States
d Cross-sectional study to evaluate eco-
nomic and QoL impact of SS in
women
d DEDIQ Primary/secondary
SS (N¼45)
d DED symptoms:
- Affected lifestyle and leisure activ-
ities in z60% of patients
- Interfered with effectiveness at
work in 37.5% of patients
Asia
Mizuno et al 201041 Japan d Multicenter prospective cohort study
to assess impact of DED on QoL and
associations between symptoms and
ocular surface ﬁndings
d VFQ-25
d SF-8
DED (N¼158), of
whom had SS
(n¼60), non-SS DED
(n¼98)
d Some patients with DED recorded
extremely low VFQ-25 scores
d Lower SF-8 PCS and MCS scores
versus healthy individuals
- Differences between patients with
SS and non-SS DED not signiﬁ-
cantly different
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160 THE OCULAR SURFACE / APRIL 2016, VUS study, data for patients with DED that initiated treat-
ment with topical cyclosporine (Restasis, Allergan, Inc.,
Irvine, CA) or punctal plugs were analyzed from a research
database containing health plan enrollment, medical claims,
and pharmacy claims data (extracted for 2004e2005).12 Of
the commercial health plan enrollees who met inclusion
criteria, 9,065 had received topical cyclosporine and 8,758
had received punctal plugs. The annual total mean health
plan costs were US $3.05 million for the topical cyclosporine
cohort (US $336 per patient) and US $3.28 million for the
punctal plug cohort (US $2.24 million [US $256 per patient]
for initial punctal plug procedures and an additional US
$1.04 million [US $307 per patient] for subsequent proce-
dures during the 365-day follow-up period).
c. Asia
The literature on direct costs in Asia is more limited
than in Europe and the United States, with no studies
from China and only one small cohort study in Japan. In
this study, Mizuno et al evaluated direct DED-related costs
for 2008 among 118 patients with DED using outpatient
medical records and survey questionnaires.6 Direct costs
were composed of medical and drug costs, including costs
related to artiﬁcial tear use and punctal plugs. Direct annual
costs per patient were estimated at U52,467 (US $530),
comprising clinical costs of U16,318 (US $165), drug costs
of U32,000 (US $323), and costs for punctal plugs of
U4149 (US $42).
2. Treatment Utilization and Costs
a. Europe
In the study by Clegg et al, the cost of prescription drugs
varied across France, Germany, Italy, Spain, and the United
Kingdom, with the cost per 1,000 patients with DED
ranging from US $22,000 in France to US $535,000 in the
United Kingdom for 2003 to 2004.9 It should be noted
when comparing these data with other regions that topical
cyclosporine (which was associated with an increase in pre-
scription costs after its introduction in the United States13)
is not currently available in Europe.
b. United States
Of the US literature identiﬁed, two studies examined
overall DED-related prescription costs.13,14 A retrospective
study by Galor et al reviewed the expenditures of 147 partic-
ipants in the Medical Expenditure Panel Survey (a subsam-
ple of the US National Health Interview Survey). This study
showed that the total number of prescriptions for treatments
for DED increased substantially after the introduction of
topical cyclosporine in 2003,13 with the cost associated
with DED prescription medications increasing from a
mean US $55 per patient per year in 2001-2002 to US
$299 per patient per year in 2005-2006. The Medical Expen-
diture Panel Survey also showed that mean annual DED
medication expenditure per patient for females was twice
that of males (US $244 vs US $122; P<.0001), while age
was not found to be a signiﬁcant factor after controlling
for other covariates. In the second study, which wasOL. 14 NO. 2 / www.theocularsurface.com
ECONOMIC AND HUMANISTIC BURDEN OF DRY EYE DISEASE / McDonald, et alpublished in 2003, the annual cost of using palliative medi-
cations, punctal plugs, and surgery to manage and treat
DED was estimated to be US $357,050 for an organization
covering 500,000 lives.14 Three additional studies investi-
gated the cost and cost-effectiveness of treatment with
topical cyclosporine.5,12,15 Notable among these was the
claims analysis by Fiscella et al, which reported mean treat-
ment cost per patient at US $336 for topical cyclosporine
and US $375 for punctal plug procedures in the 1-year
follow-up period (2004e2005).12 One further study re-
ported unit costs of medications, surgical procedures, and
health care professional visits for patients with DED in
2003.7
c. Asia
As reviewed above, Mizuno et al estimated that in Japan,
the total annual direct drug cost per patient was U32,000
(US $323), and the annual cost of punctal plugs was
U4,149 (US $42) in 2008.6 It is worth noting that these costs
were estimated before diquafosol ophthalmic solution
(Diquas, Santen Pharmaceutical Co., Ltd., Osaka, Japan)
became available in Japan in 2010, so drug costs might be
expected to be higher after this date. Topical cyclosporine
also was unavailable in Japan at the time of the study. Our
literature search did not identify any studies reporting treat-
ment utlization or costs in China.
3. Productivity Loss and Related Indirect Costs
a. Europe
No literature was identiﬁed reporting on DED-related
productivity loss or indirect costs in Europe.
b. United States
We identiﬁed four studies from the United States that
examined productivity loss and indirect costs related to
DED.8,14,16,17 In the study by Yu et al, the average annual in-
direct DED cost to society for 2008 was estimated at US
$11,302 per patient owing to reduced productivity.8 The au-
thors estimated that this corresponds to a total burden of
productivity loss and related indirect cost of US $55.4 billion
in the United States. The study also measured reductions in
productivity owing to absenteeism (the loss of working time
owing to absence or leaving early) and presenteeism
(impairment at work/reduced on-the-job effectiveness) us-
ing the Work Productivity and Activity Impairment Ques-
tionnaire. The level of both presenteeism and absenteeism
differed according to the severity of DED: the number of
days lost per year owing to affected performance was esti-
mated at 91, 94.9, and 128.2 days for mild, moderate, and
severe DED, respectively, and the estimated direct number
of work days lost per year was 8.4, 3.7, and 14.2 days, respec-
tively.8 In a cross-sectional, web-based survey that also used
the Work Productivity and Activity Impairment Question-
naire, reduced productivity while at work was reported at
all levels of disease severity (mild, moderate, and severe
DED).17 Further evidence of the negative impact of DED
on work productivity was provided by a study published
in 2000, in which patients with DED reported 184 workTHE OCULAR SURFACE / APRIL 2016, VOLdays of reduced productivity per year (estimated at US
$5,362 per individual).14 Another study reported that a sam-
ple of SS patients with DED worked 208 days of the year
with DED symptoms and were absent from work for
5 days owing to their DED symptoms/treatment.16
c. Asia
Only one study reporting the impact of DED on work
productivity was identiﬁed from Japan, with no studies
from China. In the Japanese study, the impact of DED on
the work productivity of 355 ofﬁce workers was evaluated
using the Japanese version of the Work Limitations Ques-
tionnaire (cost extracted 2011).18 Participants were grouped
into four categories according to diagnosis by an ophthal-
mologist and subjective symptoms. These were deﬁnite
DED (diagnosis and symptoms), marginal DED (diagnosis
but no symptoms), self-reported DED (symptoms but no
diagnosis), and controls (no diagnosis or symptoms). Pro-
ductivity was signiﬁcantly lower in participants with self-
reported DED compared with controls (P<.05), with the
annual cost of work productivity loss associated with DED
estimated at US $741 (U59,758) per patient.
In addition, work performance in the self-reported DED
group was signiﬁcantly lower compared with controls
(P<.05; work performance loss: self-reported DED, 6.06%,
controls, 4.27%).
B. HRQoL Burden of DED
The studies meeting our selection criteria for inclusion
in the systematic review quantitatively and qualitatively
assessed HRQoL in patients with DED using a variety of in-
struments, including DED-speciﬁc, vision-speciﬁc, generic,
work productivity, and anxiety/depression instruments.
These instruments are summarized in Table 4 for reference.
1. Europe
Overall, we identiﬁed 11 studies in Europe that reported
HRQoL measures either in patients diagnosed with
DED19-23 or those with primary SS.24-29 The studies con-
ducted in SS patients did not distinguish the burden attrib-
utable to DED from that due to other aspects of SS. We
included these studies on the basis that DED is a key clinical
manifestation of SS.2,30 However, it should be noted that the
DED in SS is generally more severe than non-SS DED31 and
therefore the burden is likely to be greater. All 11 studies
demonstrated a signiﬁcant negative effect of DED/primary
SS on at least some aspects of HRQoL.
The most frequently used DED- or vision-speciﬁc instru-
ment was the Ocular Surface Disease Index (OSDI), which is
designed to assess DED-related HRQoL across three sub-
scales: ocular symptoms, vision-related activities of daily
living, and environmental triggers. A cross-sectional case-
control study reported signiﬁcantly higher (worse) OSDI total
scores and signiﬁcantly lower (worse) 25-item Visual Func-
tion Questionnaire (VFQ-25) scores in patients with DED
compared with controls.22 Three prospective studies also re-
ported signiﬁcantly worse OSDI overall scores for the. 14 NO. 2 / www.theocularsurface.com 161
Table 4. Instruments used to assess HRQoL/symptoms in DED
Instrument Summary
DED and vision speciﬁc
DEDIQ15,54 33 items that evaluate DED symptoms and consequent
actions taken by patients
DEQ 200156 21 items that evaluate the prevalence, frequency, diurnal
severity, and intrusiveness of DED symptoms (1e5 scale;
0¼best, 100¼worst)
ESSDAI57 Clinical index of disease activity measurement based on the
assessment of 12 organ domains (constitutional, lymphade-
nopathy, glandular, articular, cutaneous, pulmonary, renal,
muscular, peripheral nervous system, central nervous system,
hematological, and biological; 0e123 scale; higher scores
indicate worse disease activity)
ESSPRI58 Index of the mean score of key primary SS symptoms: dry-
ness, pain, and fatigue (0e10 scale; higher scores asociated
with worse disease activity)
IDEEL36 57 questions comprising three modules: dry eye symptom-
related bother, impact on daily life, and treatment satisfaction
(0e100 scale; higher scores indicate better QoL, worse
symptoms, and better treatment satisfaction)
OSDI59 Patient-reported index consisting of 12 questions covering
three domains: ocular symptoms, vision-related function, and
environmental triggers (0e100 scale; 0¼no disability,
100¼complete disability)
VAS2 Psychometric response scale used to grade a speciﬁc disease
symptom or attitude, e.g., ocular discomfort, dryness (0
e100 mm scale; 100 mm maximum)
VFQ-2560 25-item version of the 51-item NEI-VFQ. Consists of ﬁve
nonvisual domains (general health, mental health, depen-
dency, social function, role limitations) and seven visual do-
mains (general vision, distance vision, peripheral vision,
driving, near vision, color vision, and ocular pain; 0e100 scale;
0¼worst, 100¼best)
Generic
HAQ61 Eight domains of physical function; ability to perform daily
activities is rated on a ﬁve-point scale (0¼without difﬁculty;
4¼unable to do)
EQ-5D62 Five measures of health outcome are assessed (mobility, self-
care, usual activities, pain/discomfort, and anxiety/depression;
0e100 scale; higher scores indicate better overall health
status)
ESS63 Index that measures average daytime sleepiness (0e24 scale;
score 10 indicates excessive level of daytime sleepiness)
SF-3664 36 questions yield a proﬁle of two health component sum-
mary measures (PCS and MCS) and eight health domain
scales: role-physical, role-emotional, vitality, mental health,
social functioning, bodily pain, physical functioning, and
general health (0e100 scale; higher scores indicate better
self-perceived health)
Utility assessment questionnaire38 Tool for quantifying the relative impact of a speciﬁc disease
on HRQoL. Utility values can be measured by methods such
as SG or TTO (adjusted to scores from 1.0¼perfect health to
0.0¼death; scores closer to 1.0 indicate better QoL)
Table 4. continues on the following page
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Table 4. Instruments used to assess HRQoL/symptoms in DED (continued from previous page )
Instrument Summary
WHOQOL-BREF65 Cross-cultural measurement tool; comprises 26 items that
address four domains: physical health, psychological health,
social relationships, and environment (higher scores indicate
higher QoL)
Anxiety and depression
HADS66 14-item scale that determines levels of anxiety and depres-
sion in people with physical health problems (0e42 scale;
higher scores indicate worse mental health)
ZSAS67 20-item self-report assessment survey that measures anxiety
levels (score, 20e80; normal range, 20e44)
ZSDS68 20-item self-report assessment survey that measures
depressed status (score, 25e100; normal range, 25e49)
DED, dry eye disease; DEDIQ, Dry Eye Disease Impact Questionnaire; DEQ, Dry Eye Questionnaire; EQ-5D, EuroQol 5-Dimensions; ESS, Epworth
Sleepiness Scale; ESSDAI, European League Against Rheumatism Sjögren’s Syndrome Disease Activity Index; ESSPRI, European League Against
Rheumatism Sjögren’s Syndrome Patient-Reported Index; HADS, Hospital Anxiety and Depression Scale; HAQ, Health Assessment Questionnaire;
HRQoL, health-related quality of life; IDEEL, Impact of Dry Eye on Everyday Life questionnaire; MCS, mental component summary; NEI-VFQ,
National Eye Institute Visual Function Questionnaire; OSDI, Ocular Surface Disease Index; PCS, physical component summary; QoL, quality of
life; SF-36, 36-item Short-Form Health Survey; SG, standard gamble; SS, Sjögren’s syndrome; TTO, time trade-off; VAS, visual analog scale; VFQ-
25, 25-item Visual Function Questionnaire; WHOQOL-BREF, World Health Organization Quality of Life-BREF scale; ZSAS, Zung Self-Rating Anxiety
Scale; ZSDS, Zung Self-Rating Depression Scale.
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In two of these studies, results were given for individual OSDI
subscales, all of which were shown to be signiﬁcantly worse
than controls.20,21 A further study that included the OSDI re-
ported correlation between patient-assessed severity and
OSDI scores (P¼.0005).19 The primary aim of this study
was to assess utility values associated with DED; results
showed that severe dry eye utilities were comparable
with those reported for dialysis and severe angina. Overall
ocular health also was shown to be lower in patients who
self-rated themselves as severe compared with those who
self-rated themselves as mild/moderate according to VFQ-
25 scores.
Among the generic HRQoL instruments, the most
frequently used was the 36-item Short-Form Health Survey
(SF-36) questionnaire, which assesses various aspects of
HRQoL (role-physical, role-emotional, vitality, mental
health, social functioning, bodily pain, physical functioning,
and general health). Two studies reported lower (worse)
scores across all eight SF-36 scales in patients with primary
SS compared with population-based control reference
values24 or normative community data.28 A third UK survey
reported that patients with primary SS had signiﬁcantly
worse SF-36 and World Health Organization Quality of
Life-BREF scale scores compared with controls.25
In a UK study that evaluated patients with primary SS
using the Health Assessment Questionnaire (HAQ), greater
functional impairment (higher HAQ scores) in patients with
primary SS versus controls was reported across all domains
of activity (P¼.0002 for HAQ total scores).26 Functional
impairment also was found to be signiﬁcantly associatedTHE OCULAR SURFACE / APRIL 2016, VOLwith the following clinical features of primary SS: fatigue,
pain, overall symptom burden, systemic disease activity,
dryness, depression, and HRQoL (all P<.0001).
Two studies in Europe used anxiety/depression instru-
ments to assess the impact of primary SS.27,29 One study re-
ported that the mean Hospital Anxiety and Depression Scale
score for depression in patients with primary SS was signif-
icantly higher (worse) compared with controls, although
that there was no signiﬁcant difference in scores for anxi-
ety.29 A second study from Italy reported that patients
with primary SS had similar scores on the Zung Self-
rating Anxiety/Depression Scales (corresponding to border-
line depression/anxiety) compared with those in patients
with systemic lupus erythematosus.27
2. United States
We identiﬁed eight studies in the United States that
assessed the impact of DED on HRQoL, all of which demon-
strated a signiﬁcant negative effect of DED on some aspects
of HRQoL.
Five US studies evaluated HRQoL measures according to
DED severity.32-36 In a validation study of VFQ-25, in which
DED severity was classiﬁed according to the European
criteria for keratoconjunctivitis sicca, a signiﬁcantly lower
(worse) mean ocular pain subscale score was reported for
patients with moderate to severe DED compared with pa-
tients with milder DED.33 A second US study assessed the
relative burden of DED in patients with non-SS DED and
SS versus a US normative sample by recruited severity (con-
trol, non-SS DED, SS) based on previous diagnosis, patient
self-report (none, very mild/mild, moderate, severe/. 14 NO. 2 / www.theocularsurface.com 163
ECONOMIC AND HUMANISTIC BURDEN OF DRY EYE DISEASE / McDonald, et alextremely severe), and clinician report (none, mild, moder-
ate, severe).37 DED consistently caused bodily pain and
decreased role-physical, vitality, and general health scores
on the SF-36 subscales, but the impact was only clinically
signiﬁcant (effect size, <0.2) when DED symptoms were re-
ported as moderate or severe. Impairments in physical and
social functioning were generally greater for patients with
SS compared with those with non-SS DED. In addition,
mental health in patients with non-SS DED and SS was un-
affected by DED symptoms when DED severity was assessed
by the clinician. However, in patients who self-reported their
symptoms as severe, a negative effect was reported on
mental health (effect size, e0.14).
Further evidence relating to the effect of DED severity
on HRQoL is provided by three studies that used the
DED-speciﬁc Impact of Dry Eye on Everyday Life (IDEEL)
instrument. This instrument consists of 57 questions
covering three domains: dry eye symptom bother, impact
on daily life (including daily activities, emotional impact,
and impact on work), and treatment satisfaction. In a pro-
spective clinical trial, the mean IDEEL-symptom bother
score at baseline correlated with self-assessed DED
severity.34 In two IDEEL validation studies in which DED
severity was evaluated according to diagnosis (non-SS
DED, SS, control), patient report (none, very mild, mild,
moderate, severe, extremely severe), and clinician report
(none, mild, moderate, severe), signiﬁcant differences be-
tween severity levels were observed with most IDEEL, SF-
36, and EuroQol 5-Dimension scores.35,36
A utility assessment study conducted in patients with
mild, moderate, or severe DED assessed the impact of
DED on HRQoL using the time trade-off method. The re-
sults from this study suggest that the impact of moderate
to severe DED on patients’ HRQoL is similar to that of
moderate to severe angina and that the impact of severe
DED is similar to severe angina.38 Two further US studies
demonstrated that DED has a negative impact on activities
of daily living.39,40 In one of these, subsets of participants
from the Women’s Health and Physicians’ Health studies
were sent an 11-item questionnaire that included questions
on the impact of DED on QoL. The results indicate that pa-
tients with DED were approximately three times more likely
to have problems with reading, engaging in professional
work, using a computer, watching television, or driving.39
A second study that used the Dry Eye Disease Impact Ques-
tionnaire to survey 45 women with primary or secondary SS
demonstrated that DED has a negative effect on lifestyle and
leisure activities as well as effectiveness at work.40
3. Asia
The literature fromAsia on the impact of DEDonHRQoL
is limited, with our search identifying no studies from China,
and only one multicenter study from Japan. This study re-
ported that some patients with DED had extremely low scores
(poor QoL) on the Japanese version of the VFQ-25.41 In addi-
tion, the physical component summary and mental compo-
nent summary on the 8-item Short-Form Health Survey164 THE OCULAR SURFACE / APRIL 2016, Vwere lower (worse) than those of healthy individuals. Howev-
er, the differences between patients with SS and non-SS DED
were not signiﬁcantly different.
IV. DISCUSSION
DED is a chronic and often under-recognized ocular
condition for which the economic and HRQoL burden can
be substantial. This systematic review provides a compre-
hensive assessment of the available literature on the eco-
nomic and humanistic burden of DED in countries across
Europe, North America, and Asia.
Overall, the literature search identiﬁed only 12 and 20
articles fulﬁlling study criteria on the economic and HRQoL
burden of DED, respectively. These numbers highlight the
need for additional research on the burden of DED. Further-
more, most of the economic data were based on costs
extracted before 2008, indicating that, in particular, up-to-
date estimates of health care resource utilization and costs
associated with DED are needed. The majority of economic
data were from the United States (nine of 12 articles), and
HRQoL data were predominantly from Europe (11 articles)
and the United States (eight articles). Our literature search
identiﬁed only three studies from Japan on the economic
and humanistic burden of DED, and no studies from China.
This is a major gap in research, particularly as the preva-
lence of DED in Asia may be relatively high compared
with Western countries.42,43
Despite the limitations of the published evidence, the
available literature suggests that DED has a substantial eco-
nomic burden, with indirect costs making up the largest
proportion of the overall cost owing to a substantial loss
of work productivity. In the United States, DED is estimated
to cost US $3.84 billion from the payer’s perspective and as
much as US $55.4 billion to society.8 However, the true cost
of DED to society may be higher, given the widespread use
of over-the-counter artiﬁcial tears by individuals with DED
symptoms. Only four articles from our literature search took
account of the cost of over-the-counter preparations. Of
these, Brown et al44 gave the annual cost of artiﬁcial tears
as US $96 per patient. In a review article that did not
meet our search criteria, Gayton et al estimated that in the
United States, 7 to 10 million people spend an average US
$320 per year on artiﬁcial tears.45
While DED costs vary between countries, the results of
the economic burden of DED across regions are very
broadly comparable. For example, annual direct cost per pa-
tient, averaged across France, Germany, Italy, Spain, and the
United Kingdom, is estimated at US $664,9 US $783 in the
United States,8 and US $530 in Japan.6 Drug costs also were
found to be comparable across regions (Europe, US $2189;
United States, US $29913; Japan, US $3236). However, the
cost of DED owing to loss of productivity was estimated
to be higher in the United States compared with Japan
(US $5,362 vs $741 per patient). Given the higher prevalence
of DED in women compared with men,11,46 this may reﬂect
the lower female employment rates in Japan compared with
the United States, with approximately 70% of JapaneseOL. 14 NO. 2 / www.theocularsurface.com
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child compared with approximately one-third in the United
States.47 Work productivity costs were not available for
Europe.
The available evidence suggests that DED has an adverse
effect on overall HRQoL, function, activities of daily living,
and work productivity across the countries examined. A
number of studies also indicated that the HRQoL burden in-
creases with the severity of disease. Indeed, results from two
utility assessment studies showed that utilities for severe
DED are similar to those reported for severe angina.19,38
Given the demonstrable effect of DED on HRQoL, we
believe that the evaluation of HRQoL measures during
assessment in the clinic and during the evaluation of new
treatments for DED should be undertaken routinely in order
to fully elucidate disease severity and impact.
The evidence for the impact of DED on mental health is
more limited, with only two studies in Europe using instru-
ments designed to address this question.27,29 Unfortunately,
these studies were conducted in SS patients and the burden
of DED was not separated from other aspects of SS. Results
reported from studies outside of this review (as they did not
meet the prespeciﬁed search criteria) suggest that DED may
indeed be associated with depression.48,49 The possible asso-
ciation of depression with DED is an important consider-
ation for clinicians treating patients with DED, and may
be the result of chronic pain and the negative effects of
DED on the patient’s QoL, function, and ability to perform
everyday activities.
An inherent limitation to our systematic review is that
there is signiﬁcant variability in methods/reporting across
the studies identiﬁed, including the DED identiﬁcation/cate-
gorization methods, patient ages, time of assessments,
methods of data collection/reporting, and HRQoL instru-
ments used. This variability limits comparability of identi-
ﬁed data. Another limitation of our literature search was
that the upper limit of the search was July 2013, so relevant
articles after that date would not have been captured. In
addition, because a signiﬁcant number of the articles we
reviewed contained data extracted before 2008, estimates
of the economic impact and costs for medical treatment
and medications for DED are expected to be higher. Older
studies might have underestimated the incidence of DED
if MGD was not considered part of the deﬁnition of DED,
as per the 2007 International Dry Eye Workshop
(DEWS)2 and International Workshop on MGD.50 In addi-
tion, it is known that some DED patients with objective ev-
idence of DED may have an absence of speciﬁc
symptoms.51,52 This could also lead to an underestimation
of DED when classiﬁcation relies on patient self-report.
V. CONCLUSIONS
Although published data are limited, the available evi-
dence suggests that DED has a substantial negative impact
on physical, and potentially psychological, function and
QoL, resulting in a large humanistic burden on patients.
In addition, DED has a substantial economic burden, withTHE OCULAR SURFACE / APRIL 2016, VOLindirect costs making up the largest proportion of the over-
all cost. Additional data are needed, particularly in Asia, in
order to gain a better understanding of the burden of DED
and help inform future resource utilization.
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